Article
Bluebird falls on worries over $2.8 mln gene therapy's commercial success
Rating:
0.0
Views:
51
Likes:
1
Library:
1
Bluebird bio slumped nearly 15% on Thursday as investors fretted over sales potential of its newly approved ultra-rare blood disorder gene therapy that is the most expensive treatment to date at $2.8 million.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value